We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
US-based biotechnology firm Orca Bio has raised $192m in a Series D financing round to support the development of cell therapies intended to provide an alternative for standard bone marrow transplants.